Cartesian to Spotlight Autoimmune Pipeline at Premier Investor Conferences

FREDERICK, MD – February 23, 2026 – Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company, is preparing for a series of high-stakes presentations at three major investor conferences in March and April. The company announced its management will participate in the TD Cowen Health Care Conference, Leerink’s Global Healthcare Conference, and the Needham Virtual Healthcare Conference, providing a crucial platform to detail the progress of its pioneering cell therapy pipeline. The focus will undoubtedly be on its lead asset, Descartes-08, which is advancing through late-stage trials for autoimmune diseases and represents a potential paradigm shift in treatment.

The Strategic Importance of the Investor Spotlight

For a clinical-stage company like Cartesian Therapeutics, these upcoming conference appearances are far more than routine corporate communications. They represent a strategic imperative to engage with the investment community at a pivotal moment. With its lead candidate in a costly Phase 3 trial, maintaining investor confidence, attracting potential partners, and ensuring financial stability are paramount. The presentations and fireside chats offer a direct channel to articulate the company's value proposition and differentiate its science in a competitive and capital-intensive industry.

Biotechnology is a sector fueled by innovation but funded by capital. As companies move from early-stage research to late-stage development, the financial stakes escalate dramatically. These conferences—attended by institutional investors, financial analysts, and larger pharmaceutical companies—are critical venues for securing the resources needed to complete clinical trials, navigate the regulatory process, and prepare for potential commercialization. For Cartesian, this means reinforcing the narrative around the promise of Descartes-08 and its underlying mRNA cell therapy platform.

Redefining Cell Therapy Beyond Cancer

Cartesian Therapeutics is at the forefront of a significant scientific movement: applying cell therapy, specifically CAR-T technology, beyond its initial success in oncology to the complex world of autoimmune diseases. The company's lead asset, Descartes-08, is an autologous anti-BCMA mRNA CAR-T therapy. In simple terms, it uses a patient's own T cells, which are engineered outside the body using messenger RNA (mRNA) to recognize and eliminate B-cells that produce disease-causing antibodies.

What sets Descartes-08 apart from conventional DNA-based CAR-T therapies is its innovative design. By using mRNA, the therapeutic effect is potent but transient, and it avoids the risk of permanently altering a patient's genome. This has profound implications for safety and administration. Critically, Descartes-08 is designed to be administered in an outpatient setting without the need for harsh preconditioning chemotherapy that is standard for cancer CAR-T treatments. This approach has so far yielded a favorable safety profile in clinical trials, with no observed cases of severe side effects like cytokine release syndrome (CRS) or neurotoxicity (ICANS), which can complicate conventional CAR-T treatments.

This improved safety profile and convenience could be a game-changer for patients with chronic autoimmune conditions, offering a powerful therapeutic option without the significant burden and risk associated with lymphodepletion.

Clinical Momentum Builds for Descartes-08

The investment community will be keenly focused on clinical updates, and Cartesian has significant progress to report. The company's most advanced program is for generalized myasthenia gravis (gMG), a debilitating autoimmune disorder that causes muscle weakness. The Phase 3 AURORA trial for Descartes-08 in gMG is currently enrolling patients, with its design bolstered by a Special Protocol Assessment agreement from the U.S. Food and Drug Administration (FDA).

This late-stage trial follows highly encouraging results from a Phase 2b study. In that trial, 71% of patients treated with Descartes-08 achieved a clinically meaningful improvement in disease severity at three months, compared to just 25% of patients who received a placebo. Furthermore, long-term follow-up data showed deep and durable responses, with patients experiencing an average 4.8-point reduction in the MG-Activities of Daily Living (MG-ADL) score—a key measure of functional impairment—at the 12-month mark. The therapy has already received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the FDA for this indication, underscoring its potential to address a significant unmet need.

Cartesian is also actively expanding the potential applications of its platform. The company plans to initiate a Phase 2 trial, known as TRITON, for Descartes-08 in myositis in the first half of 2026. Myositis, a group of conditions causing chronic muscle inflammation, affects an estimated 80,000 people in the U.S. and remains a significantly underserved market. The company has also reported promising early signals in a Phase 2 trial for systemic lupus erythematosus (SLE) and has initiated a Phase 1/2 pediatric trial (HELIOS) for juvenile dermatomyositis, highlighting the broad potential of its therapeutic approach.

Navigating a Crowded and Evolving Market

While its science is innovative, Cartesian Therapeutics operates in a dynamic and competitive market. The global gMG treatment market is valued at over $1.5 billion and is projected to grow substantially, driven by an increasing prevalence of autoimmune diseases and new therapeutic options. The field is currently dominated by major players like AstraZeneca and Argenx, whose antibody-based therapies have improved patient outcomes but can require chronic administration and carry risks of immunosuppression.

Cartesian's key differentiator—and a central part of its investment thesis—is the potential for Descartes-08 to induce deep, durable remissions after a short course of treatment, all with a more favorable safety profile that allows for outpatient care. During the upcoming conferences, management will be tasked with clearly articulating how this unique combination of efficacy, safety, and convenience positions Descartes-08 to capture a significant share of the market and address the lingering unmet needs of patients who do not respond adequately to existing therapies.

Financial Runway and Analyst Outlook

Underpinning the company's ambitious clinical plans is its financial health. As of its latest reports, Cartesian had approximately $145.1 million in cash, which it states is sufficient to fund operations into mid-2027. This runway is expected to cover the completion of the pivotal Phase 3 AURORA trial in gMG. The company's cash position was strengthened by a $130 million private placement in 2024, demonstrating investor support for its long-term strategy.

Wall Street has largely responded with optimism. The consensus among analysts covering the stock (RNAC) is a 'Strong Buy,' with average 12-month price targets suggesting significant upside from its current trading level. However, investors will be listening intently for updates on clinical enrollment, manufacturing progress, and pipeline expansion to validate these bullish forecasts.

The upcoming presentations provide a critical opportunity for Cartesian Therapeutics to reaffirm its trajectory. By showcasing its robust clinical data and outlining a clear strategic path forward, the company aims to solidify investor confidence as it works to deliver what could be the first-ever CAR-T therapy for autoimmune disease.